NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)

被引：1
|
作者：
De Vincenzo, F.
Rossoni, G.
Santoro, A.
Gregorc, V.
Zucali, P. A.
Citterio, G.
Simonelli, M.
Petrella, G.
Caligaris-Cappio, F.
Lambiase, A.
Bordignon, C.
机构：
[1] Humanitas Canc Ctr, Rozzano, Italy
[2] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[3] MolMed SpA, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.7089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7089
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Combined modality treatment for malignant pleural mesothelioma (MPM)
    Nafteux, Ph.
    Nackaerts, K.
    Lievens, Y.
    Vansteenkiste, J.
    Demedts, M.
    Van den Bogaert, W.
    Lerut, T.
    LUNG CANCER, 2006, 52 : S26 - S26
  • [42] Molecular prognostic markers in Malignant Pleural Mesothelioma (MPM)
    Bahnassy, Abeer A.
    Gaafar, Rabab M.
    Zekri, Abdel-Rahman N.
    Abdelrahman, Abdelrahman M.
    Aboulkassem, Fatma A.
    Elsherif, Ghada M.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S757 - S757
  • [43] Combined modality treatment for Malignant Pleural Mesothelioma (MPM)
    Nackaerts, Kristiaan
    Nafteux, Philippe
    Lievens, Yolande
    Vansteenkiste, Johan
    Demedts, Maurits
    van den Bogaert, Walter
    Lerut, Toni
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S429 - S429
  • [44] STATIN USE AND SURVIVAL IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Cedres, S.
    Navarro, A.
    Martinez, A.
    Martinez, P.
    Ortiz, C.
    Farias, L.
    Felip, E.
    ANNALS OF ONCOLOGY, 2015, 26
  • [45] Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
    Lorusso, D.
    Scambia, G.
    Amadio, G.
    di Legge, A.
    Pietragalla, A.
    De Vincenzo, R.
    Masciullo, V.
    Di Stefano, M.
    Mangili, G.
    Citterio, G.
    Mantori, M.
    Lambiase, A.
    Bordignon, C.
    BRITISH JOURNAL OF CANCER, 2012, 107 (01) : 37 - 42
  • [46] Pemetrexed and carboplatin in the treatment of malignant pleural mesothelioma (MPM)
    Papi, M.
    Genestreti, G.
    Tassinari, D.
    Tamburini, E.
    Nicoletti, S.
    Nicolini, M.
    Fabbri, P.
    Fabbri, P.
    Santo, A.
    Pasquini, E.
    Ravaioli, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM)
    Pinelli, Valentina
    Sivori, Massimiliano
    Canessa, Pier Aldo
    Fontana, Vincenzo
    Pistillo, Maria Pia
    Ferro, Paola
    Franceschini, Maria Cristina
    Vigani, Antonella
    Roncella, Silvio
    Battolla, Enrico
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [48] Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
    D Lorusso
    G Scambia
    G Amadio
    A di Legge
    A Pietragalla
    R De Vincenzo
    V Masciullo
    M Di Stefano
    G Mangili
    G Citterio
    M Mantori
    A Lambiase
    C Bordignon
    British Journal of Cancer, 2012, 107 : 37 - 42
  • [49] Activity and Safety of Trabectedin in patients with Sarcomatoid/Biphasic Malignant Pleural Mesothelioma (MPM)
    Cortinovis, D.
    Hollander, L.
    Floriani, I.
    Grosso, F.
    Marinello, A.
    Ceresoli, G. L.
    Pacchetti, I.
    Zucali, P. A.
    Tiseo, M.
    D'Incalci, M.
    Canova, S.
    Ugo, F.
    Vukcaj, S.
    Abbate, M. I.
    Zai, S.
    Bidoli, P.
    ANNALS OF ONCOLOGY, 2015, 26 : 75 - 75
  • [50] Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)
    Cedres, S.
    Cruellas, M.
    Assaf, J. D.
    Iranzo, P.
    Callejo, A.
    Pardo, N.
    Navarro, A.
    Martinez-Marti, A.
    Carbonell, C.
    Frigola, J.
    Amat, R.
    Gonzalo, J.
    Navarro, V.
    Dienstmann, R.
    Balmana, J.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S323 - S324
12345